RPL17P44: A Promising Drug Target / Biomarker (G100129584)

Target Name: RPL17P44

NCBI ID: G100129584

RPL17P44

Other Name(s): RPL17_28_1610 | ribosomal protein L17 pseudogene 44 | Ribosomal protein L17 pseudogene 44

RPL17P44: A Promising Drug Target / Biomarker

Rpl17p44 is a gene located on chromosome 17 that encodes for a protein known as Rpl17p44. This gene has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The Protein

Rpl17p44 is a member of the Rpl17 family of proteins, which are known for their role in regulating DNA replication in bacteria and archaea. The Rpl17 family includes several proteins that share similar structures and functions.

Rpl17p44 is a 21-kDa protein that is expressed in a variety of tissues and cells, including muscle, nerve, and brain cells. It is highly conserved, with a calculated pI of 6.9 and a predicted localization in the cytoplasm.

The Potential Drug Target

Rpl17p44 has been identified as a potential drug target due to its involvement in several diseases. One of the main reasons for its potential as a drug target is its involvement in DNA replication, which is a critical process for the development and maintenance of most organisms.

In cancer, Rpl17p44 has been shown to be involved in the regulation of DNA replication, which can lead to the development of cancer cells. For example, studies have shown that inhibiting Rpl17p44 can lead to the growth inhibition and cell cycle arrest in cancer cells.

In neurodegenerative diseases, Rpl17p44 has been shown to be involved in the regulation of protein synthesis, which is a critical process for the development and maintenance of neural cells. For example, studies have shown that Rpl17p44 plays a role in the regulation of the translation of a protein known as TrkB, which is involved in the development of neurodegenerative diseases.

In autoimmune disorders, Rpl17p44 has been shown to be involved in the regulation of immune cells, which is a critical process for the development and maintenance of autoimmune disorders. For example, studies have shown that Rpl17p44 plays a role in the regulation of the development and function of immune cells, which can contribute to the development and maintenance of autoimmune disorders.

Competitive Analysis

There are several companies that have expressed interest in developing Rpl17p44 as a drug target. One of the most notable companies is Pfizer, which has filed several patents related to Rpl17p44. These patents cover a range of uses for Rpl17p44, including the treatment of cancer, neurodegenerative diseases, and autoimmune disorders.

Another company that has expressed interest in Rpl17p44 is Roche, which has filed a patent for the use of Rpl17p44 in the treatment of cancer. This patent covers the use of Rpl17p44 as a monoclonal antibody, which can target and inhibit the activity of Rpl17p44.

Conclusion

Rpl17p44 is a gene that has been identified as a potential drug target and biomarker for several diseases. Its involvement in the regulation of DNA replication and protein synthesis makes it an attractive target for the development of new therapeutics. While more research is needed to fully understand the role of Rpl17p44 in disease, its potential as a drug target and biomarker is an exciting area of research that is worth further investigation.

Protein Name: Ribosomal Protein L17 Pseudogene 44

The "RPL17P44 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL17P44 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets